View on Pubmed.gov 27879264 | View on doi.org 10.1158/0008-54...
Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts.
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
- Program in Systems Biology and Program in Molecular Medicine, University of Massachusetts, Worcester, Massachusetts.
- Onami team, The Systems Biology Institute, Tokyo, Japan.
- Laboratory for Developmental Dynamics, RIKEN Quantitative Biology Center, Hyogo, Japan.
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts. carl_novina@dfci.harvard.edu.
Abstract
Small molecules and antisense oligonucleotides that inhibit the translation initiation factors eIF4A1 and eIF4E have been explored as broad-based therapeutic agents for cancer treatment, based on the frequent upregulation of these two subunits of the eIF4F cap-binding complex in many cancer cells. Here, we provide support for these therapeutic approaches with mechanistic studies of eIF4F-driven tumor progression in a preclinical model of melanoma. Silencing eIF4A1 or eIF4E decreases melanoma proliferation and invasion. There were common effects on the level of cell-cycle proteins that could explain the antiproliferative effects in vitro Using clinical specimens, we correlate the common cell-cycle targets of eIF4A1 and eIF4E with patient survival. Finally, comparative proteomic and transcriptomic analyses reveal extensive mechanistic divergence in response to eIF4A1 or eIF4E silencing. Current models indicate that eIF4A1 and eIF4E function together through the 5'UTR to increase translation of oncogenes. In contrast, our data demonstrate that the common effects of eIF4A1 and eIF4E on translation are mediated by the coding region and 3'UTR. Moreover, their divergent effects occur through the 5'UTR. Overall, our work shows that it will be important to evaluate subunit-specific inhibitors of eIF4F in different disease contexts to fully understand their anticancer actions. Cancer Res; 77(3); 613-22. ©2016 AACR.
References
Genes Dev. 2004 Apr 1;18(7):745-54
Cell. 2015 Oct 8;163(2):292-300
Mol Cell. 2014 Oct 2;56(1):79-89
Cell. 2015 Jul 2;162(1):59-71
Cited by 27 citations (total)
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Translation initiation factors and their relevance in cancer.
Electronic publication date March 6, 2019
Columba de la Parra [...] Robert J Schneider et al.
Deregulation of several translation initiation factors occurs in numerous types of cancers. Translation initiation factors are not merely ancillary players...
Journal Article
Cellular delivery of dinucleotides by conjugation with small molecules: targeting translation initiation for anticancer applications.
Electronic publication date August 12, 2021
Natalia Kleczewska [...] Jacek Jemielity et al.
Targeting cap-dependent translation initiation is one of the experimental approaches that could lead to the development of novel anti-cancer therapies....
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
Copyright
©2016 American Association for Cancer Research.